Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC. Zhao B, Yao L, Ma W. J Thorac Oncol 2024;19:e5-e6.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao B, Yao L, Ma W. Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC. J Thorac Oncol 2024;19:e5-e6.
PMID: 38719426